Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Inventory (2023 - 2025)

Krystal Biotech's Inventory history spans 3 years, with the latest figure at $40.5 million for Q4 2025.

  • For Q4 2025, Inventory rose 52.69% year-over-year to $40.5 million; the TTM value through Dec 2025 reached $40.5 million, up 52.69%, while the annual FY2025 figure was $40.5 million, 52.69% up from the prior year.
  • Inventory for Q4 2025 was $40.5 million at Krystal Biotech, up from $37.6 million in the prior quarter.
  • Across five years, Inventory topped out at $40.5 million in Q4 2025 and bottomed at $5.3 million in Q3 2023.
  • The 3-year median for Inventory is $22.5 million (2024), against an average of $22.2 million.
  • The largest annual shift saw Inventory soared 279.5% in 2024 before it surged 52.69% in 2025.
  • A 3-year view of Inventory shows it stood at $7.0 million in 2023, then skyrocketed by 279.5% to $26.5 million in 2024, then soared by 52.69% to $40.5 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Inventory are $40.5 million (Q4 2025), $37.6 million (Q3 2025), and $29.9 million (Q1 2025).